Cargando…
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial
IMPORTANCE: Dry eye disease (DED) is a common public health problem with significant impact on vision-related quality of life and well-being of patients. Medications with rapid onset of action and a good tolerability profile remain an unmet need. OBJECTIVE: To assess efficacy, safety, and tolerabili...
Autores principales: | Akpek, Esen K., Wirta, David L., Downing, Johnathon E., Tauber, Joseph, Sheppard, John D., Ciolino, Joseph B., Meides, Alice S., Krösser, Sonja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080403/ https://www.ncbi.nlm.nih.gov/pubmed/37022717 http://dx.doi.org/10.1001/jamaophthalmol.2023.0709 |
Ejemplares similares
-
A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study
por: Sheppard, John D., et al.
Publicado: (2021) -
A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019) -
A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
por: Tauber, Joseph, et al.
Publicado: (2021) -
Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023) -
A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye
por: Gehlsen, Uta, et al.
Publicado: (2017)